Polymorphisms and haplotypes in the caspase-3, caspase-7, and caspase-8 genes and risk for endometrial cancer: A population-based, case-control study in a Chinese population

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 7, 2009, Pages 2114-2122

  Xu, Hong Li ^a   Xu, Wang Hong ^a,b   Cai, Qiuyin ^c   Feng, Min ^a   Long, Jirong ^c   Zheng, Wei ^c   Xiang, Yong Bing ^a   Shu, Xiao Ou ^c,d  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 8;

ADULT; ALLELE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RISK; CANCER SUSCEPTIBILITY; CASP3 GENE; CASP7 GENE; CASP8 GENE; CHINESE; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR INVERSION PROBE METHOD; POPULATION BASED CASE CONTROL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; TECHNIQUE;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CASPASE 3; CASPASE 7; CASPASE 8; CHINA; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HAPLOTYPES; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCTIVE HISTORY; RISK ASSESSMENT; RISK FACTORS;

EID: 67650447987     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0152     Document Type: Article

References (48)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2002;55:74-108.
2. Gulyaeva LF, Mikhailova ON, PustyInyak VO, et al. Comparative analysis of SNP in estrogen-metabolizing enzymes for ovarian, endometrial, and breast cancers in Novosibirsk, Russia. Adv Exp Med Biol 2008;617:359-66.
3. Olson SH, Bandera EV, Orlow I. Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review. Am J Epidemiol 2007;165:235-45.
4. Hirata H, Hinoda Y, Okayama N, et al. CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer 2008;112:1964-73.
5. Kitao K, Yoshida S, Kennedy S, et al. Epidermal growth factor receptor and human epidermal growth factor receptor 2 gene polymorphisms in endometrial cancer in a Japanese population. Reprod Sci 2007;14:349-57.
6. Terry K, McGrath M, Lee IM, Buring J, De Vivo I. MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2008;17:983-6.
7. Konac E, Onen HI, Metindir J, Alp E, Biri AA, Ekmekci A. Lack of association between -460 C/T and 936 C/T of the vascular endothelial growth factor and angiopoietin-2 exon 4 G/A polymorphisms and ovarian, cervical, and endometrial cancers. DNA Cell Biol 2007;26:453-63.
8. Weiss JM, Weiss NS, Ulrich CM, Doherty JA, Chen C. Nucleotide excision repair genotype and the incidence of endometrial cancer: effect of other risk factors on the association. Gynecol Oncol 2006;103:891-6.
9. Goodfellow PJ, Buttin BM, Herzog TJ, et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A 2003;100:5908-13.
10. Thompson CB. Apoptosis is the pathogenesis and treatment of disease. Science 1995;267:1456-62.
11. Denault JB, Salvesen GS. Caspases: keys in the ignition of cell death. Chem Rev 2002;102:4489-500.
12. Boatright KM, Salvesen GS. Mechanisms of caspase activation. Curr Opin Cell Biol 2003;15:725-31.
13. Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF. Apoptosis and lung cancer: a review. J Cell Biochem 2003;88:885-98.
14. Kothakota S, Azuma T, Reinhard C, et al. Caspase 3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 1997;278:294-8.
15. Sattar R, Ali SA, Abbasi A. Molecular mechanism of apoptosis: prediction of three-dimensional structure of caspase 6 and its interactions by homology modeling. Biochem Biophys Res Commun 2003;308:497-504.
16. McDonald ER III, El-Deiry WS. Suppression of caspase 8 and 10 associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth. Proc Natl Acad Sci U S A 2004;101:6170-5.
17. Wang JX, Zheng S. Caspase 3 and survivin expression in pediatric neuroblastoma and their roles in apoptosis. Chin Med J 2004;117:1821-4.
18. Devarajan E, Sahin AA, Chen JS, et al. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene 2002;21:8843-51.
19. Isobe N, Onodera H, Mori A, et al. Caspase 3 expression in human gastric carcinoma and its clinical significance. Oncology 2004;66:201-9.
20. Palmerini F, Devilard E, Jarry A, Birg F, Xerri L. Caspase 7 down-regulation as an immunohistochemical marker of colonic carcinoma. Hum Pathol 2001;32:461-7.
21. Hu HH, Zhou SF, Li GQ, Wu YY, Gao WH. Expression of caspase 7, caspase 3, survivin in breast neoplasm and their relationship with clinicopathologic factors. J Modern Oncol 2007;15:640-2.
22. Yoo NJ, Lee JW, Kim YJ, et al. Loss of caspase 2, 6 and 7 expression in gastric cancers. APMIS 2004;112:330-5.
23. Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N. Loss of caspase 8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2000;60:4315-9.
24. Harada K, Toyooka S, Shivapurkar N, et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res 2002;62:5897-901.
25. Yang M, Sun T, Wang L, et al. Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res 2008;14:3230-6.
26. Hosgood HD III, Baris D, Zhang Y, et al. Caspase polymorphisms and genetic susceptibility to multiple myeloma. Hematol Oncol 2008;26:148-51.
27. Jang JS, Kim KM, Choi JE, et al. Identification of polymorphisms in the Caspase 3 gene and their association with lung cancer risk. Mol Carcinog 2008;47:383-90.
28. Pittman AM, Broderick P, Sullivan K, et al. CASP8 variants D302H and -652 6N ins/del do not influence the risk of colorectal cancer in the United Kingdom population. Br J Cancer 2008;98:1434-6.
29. Yoo NJ, Soung YH, Lee SH, Jeong EG, Lee SH. Mutational analysis of caspase 14 gene in common carcinomas. Pathology 2007;39:330-3.
30. Frank B, Rigas SH, Bermejo JL, et al. The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study. Breast Cancer Res Treat 2008;111:139-44.
31. Ramus SJ, Vierkant RA, Johnatty SE, et al. Consortium analysis of 7 candidate SNPs for ovarian cancer. Int J Cancer 2008;123:380-8.
32. Xu WH, Shrubsole MJ, Xiang YB, et al. Dietary folate intake, MTHFR genetic polymorphisms and the risk of endometrial cancer among Chinese women. Cancer Epidemiol Biomarker Prev 2007;16:281-7.
33. Xu WH, Xiang YB, Zheng W, et al. Weight history and risk of endometrial cancer among Chinese women. Int J Epidemiol 2006;35:159-66.
34. de Bakker PI, McVean G, Sabeti PC, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet 2006;38:1166-72.
35. Wang Y, Moorhead M, Karlin-Neumann G, et al. Allele quantification using molecular inversion probes (MIP). Nucleic Acids Res 2005;33:183.
36. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
37. Schaid DJ, Rowland CM, Tines DE, et al. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
38. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995;12:921-927.
39. Lin DY, Zeng D, Millikan R. Maximum likelihood estimation of haplotype effects and haplotype-environment interactions in association studies. Genet Epidemiol 2005;29:299-312.
40. Soung YH, Lee JW, Kim HS, et al. Inactivating mutations of CASPASE 7 gene in human cancers. Oncogene 2003;22:8048-52.
41. Judson R, Stephens JC, Windemuth A. The predictive power of haplotypes in clinical response. Pharmacogenomics 2000;1:15-26.
42. Parazzini F, La Vecchia C, Bocciolone L, Franceschi S. The epidemiology of endometrial cancer. Gynecol Oncol 1991;41:1-16.
43. Thiantanawat A, Long BJ, Brodie AM. Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res 2003;63:8037-50.
44. Zhang Y, Tounekti O, Akerman B, Goodyer CG, LeBlanc A. 17-β-estradiol induces an inhibitor of active caspases. J Neurosci 2001;21:RC176.
45. Lan Q, Zheng T, Chanock S, et al. Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphoma. Carcinogenesis 2007;28:823-7.
46. Sun T, Gao Y, Tan W, et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 2007;39:605-13.
47. Bethke L, Sullivan K, Webb E, et al. The common D302H variant of CASP8 is associated with risk of glioma. Cancer Epidemiol Biomarkers Prev 2008;17:987-9.
48. Haiman CA, Garcia RR, Kolonel LN, et al. A promoter polymorphism in the CASP8 gene is not associated with cancer risk. Nat Genet 2008;40:259-60.